What FOXO4-DRI is
FOXO4-DRI is a synthetic peptide discussed as a senolytic strategy targeting FOXO4-p53 interaction in aging research.
FOXO4-DRI is grouped under Longevity + Skin on PeptideFactCheck because it captures the part of longevity culture focused on senescent-cell clearance and headline-grabbing aging interventions.
The useful starting point is to separate the molecule itself from the internet story around it. It captures the part of longevity culture focused on senescent-cell clearance and headline-grabbing aging interventions.
Why people keep looking it up
It captures the part of longevity culture focused on senescent-cell clearance and headline-grabbing aging interventions.
FOXO4-DRI is a synthetic peptide discussed as a senolytic strategy targeting FOXO4-p53 interaction in aging research.
FOXO4-DRI tends to stay in the conversation because it touches a familiar public theme: senolytic discussion, p53 interaction, and aging biology. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Well-known longevity concept with preclinical rather than clinical support.
Human evidence is not established for the common anti-aging claims.
The main support comes from preclinical senolytic and cellular-aging work.
Why this page carries the current tier: Well-known longevity concept with preclinical rather than clinical support.
The current seed trail for FOXO4-DRI is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
This is a high-speculation area where mechanism stories often run much faster than translational evidence.
No FDA-approved FOXO4-DRI therapy is represented in this seed set.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for FOXO4-DRI. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for FOXO4-DRI is CID 167312269. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 167312269
- Formula
- C228H388N86O64
- Molecular weight
- 5358
- InChIKey
- WVZCDZFJLXBWHG-XXZPGMBKSA-N
Matched synonyms include FOXO4-DRI, FOXO4-DRI TFA salt form, 2460055-10-9.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for FOXO4-DRI returns 0 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
No linked intervention records were returned by the current ClinicalTrials.gov query terms for this page.
Literature snapshot
The current PubMed query for FOXO4-DRI returns 18 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.